TCBP TC BioPharm Ltd: רווח נקי למניה ב-12 החודשים האחרונים

TC Biopharm is developing cell therapy through alliances with oncology centers, excluding mergers. The YoY TTM EPS growth rate demonstrates the company's struggle with inflation within market cycles, where 0.00 shows the current value of the metric. Leadership in immunology enables the creation of OmnImmune drugs. Demand for tumor treatment remains stable, while the success of development depends solely on the availability of venture capital.

TC Biopharm is developing innovative cell therapy while facing logistical gaps and sanction barriers in its research. The trailing twelve-month earnings per share (EPS) trend digitizes the impact of these external constraints on bottom-line profitability. This metric measures net income growth rates, helping to balance potential returns against drawdown risk. Outperforming competitors confirms market leadership. An analysis of the trailing twelve-month EPS annual dynamics warns against overpaying for an overheated asset.